bowel cancer Colorectal cancer
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: -18 years or older. -Patients with liver metastases measurable according to RECIST in metastatic colorectal cancer. -Patients that are planned to start with capecitabine and bevacizumab treatment as determined according to Dutch guidelines. -Informed consent for longitudinal data collection according to the PLCRC study protocol.
Exclusion criteria
Exclusion criteria: • Patients receiving triple chemotherapy for mCRC. • Patients that received or currently receive any other kind of systemic therapy for cancer. • Patients that received any prior radiotherapy or surgery in the liver. • Patients with a dihydropyrimindine dehydrogenase (DPD) deficiency (heterozygous or homozygous). • Contra-indications to MRI scanning according to hospitals 7T MRI screening guideline of the UMCU. • Patients with severe liver dysfunction. • Patients with a life expectancy of
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 7T MRS characteristics on (changes in) concentration of capecitabine and metabolites measured in liver metastasis during MRS examinations obtained at discretized time point(s). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints include response measurements (complete response, partial response, stable disease and progressive disease) according to RECIST and detailed information on perfusion, diffusion and acidity as determined by functional MRI. | — |
Countries
Netherlands
Outcome results
None listed